Skip to main content
Premium Trial:

Request an Annual Quote

Santaris, Miragen Form miRNA Drug Alliance

Premium

Santaris Pharma and Miragen Therapeutics announced this week that they have formed a strategic alliance to develop microRNA-targeting drugs for cardiovascular disease.

Under the deal, Miragen will use Santaris' proprietary locked nucleic acid technology to develop single-stranded RNAs against its own miRNA targets related to cardiovascular disease. In exchange, Santaris received an undisclosed minority interest in Miragen, and is eligible to receive milestones and royalties related to the achievement of certain development and regulatory goals.

Additional terms were not disclosed.